Legend Biotech Corporation
LEGNNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for LEGN. That does not mean none is planned.
Get an email about LEGN's next catalysts
Track Legend Biotech (LEGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming events in our data (earnings, conference).See the timeline
2 upcoming, 0 past
LEGN Earnings Report
EPS Est: $0.01 | FQ end Sep/2026 | Call: bmo
Conference Presentation - CARVYKTI
For multiple myeloma. Legend Biotech announced acceptance of multiple abstracts at ASH 2026 (Dec 12-15), including new CARTITUDE-4 subgroup analyses for CARVYKTI, the CITADEL study of a preemptive steroid strategy for IEC-parkinsonism, and updated first-in-human data for in vivo CAR-T LB2501 and Phase 1 data for allogeneic LUCAR-G39D.
SourceMarket Overview
Stock performance and key metrics
No drugs found in this phase.
oncology
1 drug in this indication
Relapsed or Refractory Multiple Myeloma (RRMM)
1 drug in this indication
relapsed/refractory multiple myeloma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Legend Biotech Corporation's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Legend Biotech Corporation (LEGN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LEGN biotech catalysts?→
Add LEGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Legend Biotech Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.